[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627751":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":46,"responsibleParty":63,"collaborators":44,"id":66,"slug":44,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":44,"enrollmentInfo":75,"targetDuration":44,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":92,"whyStopped":44,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Malaya","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine-Morphine PCA (1:1 ratio)","EXPERIMENTAL","This group receives a ketamine-morphine PCA solution (1 mg mL-¹ + 1 mg mL-¹). This device deliver a 1 mL bolus, enforce a five-minute lock-out and cap delivery at 20 mL per four hours, with no background infusion. The patient will use PCA for at least 48 hours duration.",[13],"Combination Product: Ketamine-Morphine PCA",{"label":15,"type":16,"description":17,"interventionNames":18},"Morphine only PCA","ACTIVE_COMPARATOR","This group receives morphine alone PCA (1 mg mL-¹). This device deliver a 1 mL bolus, enforce a five-minute lock-out and cap delivery at 20 mL per four hours, with no background infusion. The patient will use PCA for at least 48 hours duration.",[19],"Drug: Morphine (Intravenous patient-controlled analgesia)",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","Ketamine-Morphine PCA","The patient in this group will receive PCA Morphine (1mg\u002FmL) with addition of Ketamine (1mg\u002FmL) in comparison with the other group.",[9],[27],"K-M",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Morphine (Intravenous patient-controlled analgesia)","This patient will receive PCA Morphine only (1mg\u002FmL).",[15],[34],"M",[36],{"name":37,"affiliation":5,"role":38},"SITI NADZRAH BINTI YUNUS, MBBS","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"MUHAMMAD FAEEZ BIN MOHD YUSOH, MBBS","CONTACT","+6013-5233915",null,"faeez@ummc.edu.my",[47],{"facility":48,"status":44,"city":49,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"University Malaya Medical Centre","Kuala Lumpur","59100","Malaysia",{"type":53,"coordinates":54},"Point",[55,56],101.68653,3.1412,{"lat":56,"lon":55},[59],{"name":60,"role":42,"phone":61,"phoneExt":44,"email":62},"NIK SHERINA HAIDI BINTI HANAFI, MBBS","+6079492802","niksherina@um.edu.my",{"type":38,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"MUHAMMAD FAEEZ BIN MOHD YUSOH","Postgraduate Medical Officer","100627751",false,"NCT07452705","Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery.","Patient-Controlled Analgesia (PCA) With Ketamine-Morphine (PCA KetaMorph) vs PCA Morphine for Postoperative Analgesia in Idiopathic Scoliosis Surgery - A Randomized Controlled Trial","KetaMorph","Inclusion criteria:\n\n1. Aged \\> 10 years old\n2. Idiopathic scoliosis scheduled for single-stage posterior spinal fusion (PSF).\n3. American Society of Anaesthesiologists (ASA) physical status I-II.\n\nExclusion criteria:\n\n1. Known hypersensitivity to morphine, ketamine or formulation excipients.\n2. Hepatic dysfunction (ALT or AST \\> 2 × upper limit of normal).\n3. Renal impairment (eGFR ≤ 60 mL min-¹ 1·73 m-²).\n4. Uncontrolled asthma or severe restrictive lung disease.\n5. Cardiac disease or clinically significant arrhythmia.\n6. Epilepsy.\n7. Intellectual disability precluding PCA use.\n8. Chronic opioid therapy or pre-operative pain \\> 3 months.\n9. Concomitant monoamine-oxidase inhibitor or tricyclic antidepressant therapy.\n10. History of severe postoperative delirium.","ALL","10 Years",{"count":76,"type":77},114,"ESTIMATED","INTERVENTIONAL",[80],"NA","The goal of this clinical trial is to evaluate whether adding low-dose ketamine to PCA morphine reduces opioid requirements after posterior spinal fusion surgery in adolescent idiopathic scoliosis patients. Selected patients aged 10-18 years undergoing elective AIS surgery at University Malaya Medical Centre will be randomised to ketamine-morphine or morphine-only PCA. The primary outcome is cumulative morphine consumption at 48 hours, with secondary outcomes including pain scores, opioid-related adverse effects, time to ambulation, and patient satisfaction. This study aligns with national priorities for safe opioid stewardship and enhanced peri-operative care in Malaysia.",[83],"Adolescent Idiopathic Scoliosis (AIS)",[85,86,87,88,89,90,91],"Adolescent","Analgesia","Ketamine","Morphine","Pain management","Pain-controlled","Spinal fusion","NOT_YET_RECRUITING","2026-03-01",{"date":95,"type":96},"2026-03-05","ACTUAL",{"date":98,"type":77},"2026-02-02",{"date":100,"type":77},"2028-01-30",{"name":5,"class":6},1]